Excellamol’s clinical programs are advancing injectable long-acting OncoPDCs designed to treat hard-to-reach cancers, including glioblastoma (GBM), pediatric diffuse midline glioma (DMG), and pancreatic ductal adenocarcinoma (PDAC). The Company has secured FDA alignment through two INTERACT meetings, strengthening and de-risking the path toward IND submission for its GBM pipeline.